Why is it so difficult to estimate the value of orphan drugs indicated for the treatment of rare diseases? There are a ...

Delays in drug approval cost pharmaceutical companies money. These costs include both lost sales and the additional cost if clinical trials need to last ...

Recently, the Inflation Reduction Act (IRA) is receiving a lot of attention, particularly for its provision that allows CMS to begin price negotiations for ...

The technology is amazing. Of The Economist: Fourteen years ago, Melanie Reid, a journalist, fell from a horse ...

A lot can happen in 10 years. For Alex Keuroghlian, MD, MPH (any pronoun), the last decade has certainly been a busy, productive and significant one, not only ...

The above is the title of a useful manual of Kenney and Keast (2024). Below I summarize some key points. Provide an overview of pharmacy contracts ...

See my previous posts on negotiating IRA prices in drug selection (Part 1) and sending manufacturer data (Part 2). Today we will talk about the ...

CMS launched Guidance on Negotiating IRA Prices last week. Below are some highlights on how medications will be selected. What medications are eligible ...

To account for differences in disease burden among the patient population of Medicare Advantage (MA) plans, risk adjustment based on the patient's disease ...

Today, the U.S. Department of Health and Human Services (HHS) Office for Civil Rights (OCR) published a new webpage to share answers to frequently ...